LAVAL, Aug. 3 /CNW Telbec/ - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) (“LAB”), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that LAB Research Inc. (“LRI”), its subsidiary, has closed the initial public offering of its common shares.
